Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance ...

Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that will focus on developing a ...

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and Yaskawa Electric Corporation are setting off on a joint venture to help stre | ...

Astellas and Yaskawa are establishing a joint venture for the development of a cell therapy product manufacturing platform ...

Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas"), and MBC BioLabs, a premier launchpad for early-stage life-science companies, today announced their collaboration on the ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 35.19%, which has investors questioning if this is right time to buy.

Get ready to see more of Henry Winkler on TV talking about geographic atrophy (GA). | During a quarterly conference call, as ...

NASA considers SANS one of its ‘red risks’ for a Mars mission, owing to its potential severity and the number of astronauts ...